PTK2 and cancer: Despite the single drug resistance observed with FAK inhibitors, studies have shown that combining FAK inhibitors with MAPK inhibitors can effectively eliminate compensatory ERK activation, synergistically inhibiting the migration and invasion of malignant tumors such as DGC and UM (Paradis et al., 2021; Peng et al., 2023).